Vera Therapeutics Stock Falls Despite FDA Alignment on Accelerated Review Path for Atacicept

Vera Therapeutics shares slid on Tuesday even after the company announced the FDA had aligned on an accelerated review path for atacicept, its drug targeting IgA nephropathy, a serious kidney disease. The company said Phase 3 data for atacicept is expected in the third quarter, with a regulatory filing targeted for the fourth quarter.

Despite the regulatory clarity, the stock remains down roughly 40% year to date, reflecting persistent investor skepticism about the company's ability to execute on its development and commercialization timeline. Atacicept is a dual BAFF/APRIL inhibitor that has previously shown a 46% reduction in proteinuria compared to baseline in its ORIGIN Phase 3 trial, and it carries priority review status from the FDA.